Temiye E O, Eimunjeze O P, Ogungbemi S I, Jaja S I
.
Niger J Physiol Sci. 2020 Dec 31;35(2):131-134.
Hydroxyurea is an approved therapy in the management of children suffering from sickle cell disease (SCD). In adults co-administration of hydroxyurea and L-Arginine in adult sufferers of SCD had shown some benefits. This study examined the effect of co-administration of hydroxyurea (15-35mg/kg/day) and L-Arginine (500 mg/day) for 6 weeks on blood pressure, haematological parameters, liver and antioxidant enzymes levels. The levels of these parameters when the subjects were on hydroxyurea alone were taken as control values. Results showed that the combined therapy (HU + L-Arginine) decreased SBP, DBP, MAP and PP (p <0.01 in each case) but increased %HbF, Hb and PCV (p< o.001 in each case). It elevated CAT, SOD, GPX (p < 0.001 in each case) but depressed MDA, AST, ALT and ALP (p < 0.001 in each case). The study shows that L-Arginine used as an adjunct to hydroxyurea therapy may be beneficial to children suffering from sickle cell anaemia.
羟基脲是治疗镰状细胞病（SCD）患儿的一种获批疗法。在成年SCD患者中，羟基脲与L-精氨酸联合使用已显示出一些益处。本研究考察了羟基脲（15 - 35mg/kg/天）与L-精氨酸（500mg/天）联合使用6周对血压、血液学参数、肝脏及抗氧化酶水平的影响。将受试者仅服用羟基脲时这些参数的水平作为对照值。结果显示，联合治疗（羟基脲 + L-精氨酸）可降低收缩压、舒张压、平均动脉压和脉压（每种情况p < 0.01），但可提高胎儿血红蛋白百分比、血红蛋白和红细胞压积（每种情况p < 0.001）。它可提高过氧化氢酶、超氧化物歧化酶、谷胱甘肽过氧化物酶水平（每种情况p < 0.001），但降低丙二醛、天冬氨酸转氨酶、丙氨酸转氨酶和碱性磷酸酶水平（每种情况p < 0.001）。该研究表明，L-精氨酸作为羟基脲治疗的辅助用药可能对镰状细胞贫血患儿有益。
